Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

This study is testing whether tirzepatide — a medication currently used for diabetes and weight loss — can help prevent colorectal cancer in younger adults (under 50) who are at elevated risk because they have had colon polyps removed. The study focuses specifically on early-onset colorectal cancer prevention. **You may be eligible if...** - You are between 18 and 50 years old - Your body mass index (BMI) is between 27 and 40 - You had a colonoscopy within the past 9 months and had at least two polyps removed, or one polyp that was 6mm or larger - You have never taken GLP-1 or GIP medications (e.g., semaglutide, tirzepatide, Ozempic, Mounjaro) **You may NOT be eligible if...** - You have a history of medullary thyroid cancer or a condition called MEN 2 syndrome - You have a high risk of pancreatitis or other reasons tirzepatide is contraindicated for you - You have been diagnosed with diabetes, cancer (in the past 3 years), or inflammatory bowel disease - You have a hereditary colon cancer syndrome (e.g., Lynch syndrome, familial adenomatous polyposis) - You have had bowel surgery - You are pregnant or may become pregnant during the study Talk to your doctor to see if this trial is right for you.